InflaRx

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell InflaRx and other ETFs, options, and stocks.

About IFRX

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab.

CEO

Niels Christoph Riedemann

CEONiels Christoph Riedemann

Employees

Employees74

Headquarters

Jena, Thueringen

HeadquartersJena, Thueringen

Founded

2007

Founded2007

Employees

Employees74

IFRX Key Statistics

Market cap

116.81M

Market cap116.81M

Price-Earnings ratio

-1.65

Price-Earnings ratio-1.65

Dividend yield

—

Dividend yield—

Average volume

288.98K

Average volume288.98K

High today

$1.87

High today$1.87

Low today

$1.73

Low today$1.73

Open price

$1.84

Open price$1.84

Volume

325.15K

Volume325.15K

52 Week high

$2.82

52 Week high$2.82

52 Week low

$0.8238

52 Week low$0.8238

Analyst ratings

86%

of 7 ratings

Buy

85.7%

Hold

14.3%

Sell

People also own

Based on the portfolios of people who own IFRX. This list is generated using Robinhood data, and it’s not a recommendation.